ImmunoForge, a biotech venture specializing in the development of therapeutics for rare diseases, announced that it has been finally selected for the 2026 Investment and Financing-Linked Technology Development Program (Global TIPS R&D), organized by the Ministry of SMEs and Startups (MSS) and the Korea Technology and Information Promotion Agency for SMEs (TIPA).
The program selected promising global companies in the domestic biotechnology and healthcare sectors through a two-stage evaluation process consisting of a first-round written evaluation and a second-round in-person evaluation. As a final selected company, ImmunoForge will receive a total of KRW 5 billion in government funding over the next four years.
The LMT (Leptin receptor-Mediated Transcytosis) platform, which received particular attention in this project, is based on Leptin receptor-mediated transcytosis technology. Compared with existing Blood-Brain Barrier (BBB) penetration technologies, it has clear advantages, including lower side effects and higher permeability.